Skip to main content
OpenTrials
Completed

NCT Number: NCT02800824

Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris® Rectal Aerosol Foam

To evaluate the bioequivalence between the Test Product Budesonide rectal aerosol foam and Reference Product Uceris® rectal aerosol foam after a single-dose in healthy subjects

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy, non-smoking, male and female subjects, 18 years of age or over.
  • No clinically significant findings in vital signs measurements or 12-lead electrocardiogram (ECG) or abnormal laboratory values.
  • Have no significant diseases.
  • Willing to use an acceptable, effective method of contraception.
  • Informed on the nature of the study and have agreed to and are able to read, review and sign all consent documents.
  • Have no clinically significant findings from a physical examination.

Exclusion criteria

  • Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results
  • Known history or presence of hypersensitivity or idiosyncratic reaction to budesonide, any other components of the drug products, or any other drug substances with similar activity or sodium phosphate
  • History or presence or of diabetes mellitus, glaucoma or cataracts, hypertension, or osteoporosis
  • History of drug or alcohol addiction requiring treatment.
  • History of malabsorption within the last year.
  • Presence of hepatic or renal dysfunction.
  • Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
  • Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.

Treatment and study plan

Budesonide

Drug

Uceris

Drug

Primary outcomes

  1. Maximum observed plasma drug concentration (Cmax)

    Time frame: 24 hours

  2. AUC from time 0 extrapolated to infinity (AUC0-∞)

    Time frame: 24 hours

  3. AUC from time 0 to 24 hours (AUC0-24)

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Padagis LLC

Industry

Registry information

Important dates

Primary completion
2016
First posted
Jun 15, 2016
Registry last updated
Jan 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.